Protocol Ledger

NCT05569811 · Phase II · ACTIVE NOT RECRUITING

NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial

Interventional Phase II clinical trial protocol NCT05569811 sponsored by SOLTI Breast Cancer Research Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-11-25 Enrollment: 120 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05569811
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)120 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05569811
Protocol FieldVerified Registry Value
NCT IdentifierNCT05569811
Consolidated Lead SponsorSOLTI Breast Cancer Research Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment120 participants (ESTIMATED)
Registered Start Date2022-11-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05569811
Hospital Research SiteLocationSite Profile
Hospital Clinic de BarcelonaBarcelona, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI